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Introduction
As the most prevalent cause of dementia, Alzheimer’s dis-
ease (AD) is characterized by progressive cognitive defi-
cits, amyloid plaques, neurofibrillary tangles (NFTs) and 
neuronal loss, yet it still lacks an effective cure at the pre-
sent time [21, 40]. The failure to develop successful phar-
macotherapy may, at least partially, be ascribed to the long 
pathophysiological process, which starts many years before 
the stage of symptomatic AD [43]. Therefore, much earlier 
intervention in the asymptomatic or preclinical stages may 
be required to successfully treat AD [35, 45].
Preclinical AD has been recently defined as the stages 
when amyloid is being deposited in the brain, but before 
the onset of any cognitive impairment [44]. Subjects in the 
preclinical stages are at risk for future cognitive decline 
[51]. Indeed, the lag between the appearance of amyloid 
plaques and detectable impairment in cognition is more 
than a decade [37, 44]. Growing evidence supports the 
notion that amyloid deposition disrupts functional networks 
in the brain of cognitively normal elderly [17, 32, 42, 46]. 
To have a better chance of curing AD, it is therefore crucial 
to identify pathophysiological events occurring in preclini-
cal stages that precede dementia during the initial forma-
tion of amyloid deposits.
Transgenic mouse models are essential research tools 
for uncovering AD pathogenesis as well as validating new 
therapeutic approaches. To recapitulate AD pathology, 
Abstract To successfully treat Alzheimer’s disease (AD), 
pathophysiological events in preclinical stages need to be 
identified. Preclinical AD refers to the stages that exhibit 
amyloid deposition in the brain but have normal cognitive 
function, which are replicated in young adult APPswe/
PS1deltaE9 (deltaE9) mice. By long-term in vivo two-
photon microscopy, we demonstrate impaired adaptive 
spine plasticity in these transgenic mice illustrated by their 
failure to increase dendritic spine density and form novel 
neural connections when housed in enriched environment 
(EE). Decrease of amyloid plaques by reducing BACE1 
activity restores the gain of spine density upon EE in del-
taE9 mice, but not the remodeling of neural networks. On 
the other hand, anti-inflammatory treatment with piogl-
itazone or interleukin 1 receptor antagonist in deltaE9 
mice successfully rescues the impairments in increas-
ing spine density and remodeling of neural networks dur-
ing EE. Our data suggest that neuroinflammation disrupts 
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transgenic mouse models carry familial AD gene mutations 
in the amyloid precursor protein (APP) and/or presenilins 
(PS) based on the amyloid hypothesis, which postulates an 
increased production or decreased removal of the APP pro-
teolytic fragment, amyloid β-protein (Aβ), as the primary 
cause of AD [16]. The transgenes with APP/PS mutations 
in mouse models lead to the formation of amyloid plaques 
and subsequent memory loss, but without the development 
of NFTs and massive neuronal loss [2]. Although these 
mice fail to replicate all aspects of the disease, they seem to 
faithfully imitate pre-dementia stages of AD [1].
Among the APP transgenic mouse models, APPswe/
PS1deltaE9 (deltaE9) mice have been widely used. They 
express APP with the Swedish mutation together with 
mutant human PS1 with a deletion of exon 9 [23, 39]. Inter-
estingly, in deltaE9 mice, amyloid deposition precedes typ-
ical cognitive impairments [22, 50]. Amyloid plaques start 
to emerge at the age of 4–5 months [4, 14], while the per-
formance of 7-months-old deltaE9 mice is normal in most 
cognitive tests [27, 34, 50]. The temporal lag between the 
emergence of amyloid plaques and the onset of dementia 
consequently provides a critical period to study pathophysi-
ological events related to preclinical AD.
In this study, we used long-term in vivo two-photon 
microscopy to elucidate the adaptive spine plasticity of del-
taE9 mice at young adult age. Our data demonstrated that 
deltaE9 mice failed to increase spine density and establish 
novel neural connections when exposed to enriched envi-
ronment (EE), which was caused by neuroinflammation.
Materials and methods
Animals
APPswe/PS1deltaE9 (deltaE9) mice [22] (Jackson Labo-
ratory) were crossed with GPF-M mice [10] (Jackson 
Laboratory) to obtain double transgenic offspring, which 
were heterozygous for the corresponding genes (deltaE9 
+/− × GFP +/−). GFP positive littermates without APP/
PS1 transgenes were used as controls (deltaE9 −/− × GFP 
+/−). BACE1 knockout mice [5] were also purchased 
from Jackson Laboratory, and deltaE9 +/− × Bace1 
+/− × GFP +/− (deltaE9/Bace +/−) were generated 
by interbreeding. All transgenic mice were maintained 
on C57BL/6 background. Female mice at the age of 
4–5 months were used. Mice were housed and bred in path-
ogen-free environment in the animal facility at the Centre 
for Neuropathology and Prion Research of the Ludwig-
Maximilians-University Munich (LMU), with food and 
water provided ad libidum (21 ± 1 °C, at 12/12 h light/
dark cycle). All mice were housed either singly in standard 
cages (30 × 15 × 20 cm) or in groups in environmentally 
enriched (EE) cages (80 × 50 × 40 cm) equipped with 
platforms and variety of toys, which were relocated 3 
times per week. Pioglitazone (350 ppm, Actos™) was sup-
plemented into rodent chow. All protocols and procedures 
involving animals were approved and conducted in accord-
ance with the regulations of LMU and the government of 
Upper Bavaria (Az. 55.2-1-54-2532-62-12).
Cranial window implantation and in vivo two‑photon 
imaging
The detailed surgical procedure of cranial window implan-
tation has been described previously [13, 20]. In brief, mice 
were anesthetized by intraperitoneal injection of ketamine/
xylazine (120 and 10 mg/kg, respectively). Subsequently, 
dexamethasone (6 mg/kg) was injected to prevent develop-
ment of cerebral edema. A piece of skull above the soma-
tosensory cortex was then removed carefully with a dental 
drill. The exposed brain was cleaned with sterile saline 
and covered with a round glass coverslip (D = 4 mm). 
The margin between the glass and skull was sealed with 
dental cement. Post-surgical mice were subcutaneously 
injected with carprofen (Pfizer, 4 mg/kg) and cefotaxime 
(Pharmore, 250 mg/kg). Lentiviruses (LV) encoding IL-1 
RA (LV vector was a gift from Dr. van Dam [49]) were 
intraparenchymally injected into the cortex before implant-
ing the coverslip when specified. LV encoding GFP was 
used as a control for evaluating the efficiency of IL-1 RA 
expression. The injection of the LV (200 nl per time at a 
titer of ~108 infecting units per ml) was performed at 4 
different sites in the exposed area of brain at the depth of 
700–800 µm. After 4 weeks of recovery period, mice were 
imaged by using a LSM 7MP microscope (Zeiss) equipped 
with a 20× objective (NA 1.0; Zeiss). Mice were anesthe-
tized with isoflurane (1 % in 95 % O2 and 5 % CO2) and 
placed on a heating pad to keep the body temperature at 
37 °C. Apical dendrites originating from GFP-labeled layer 
V pyramidal neurons were imaged in consecutive sessions 
(once per week). The imaging session did not last more 
than 60 min. The unique pattern of blood vessels was used 
to re-localize the imaged regions in subsequent imaging 
sessions. GFP was excited by a femtosecond laser (Spec-
tra Physics) at the wavelength of 880 nm. The intensity of 
laser and settings of data acquisition were kept constant 
during experiments. To ensure the dendrites were chosen 
in amyloid plaque-free regions, methoxy-X04 (1 mg/kg) 
was intraperitoneally injected 24 h before imaging in the 
first and last time points. Overview images were taken as 
424 × 424 × 350 µm3 (0.83 µm/pixel). From the central 
regions of these images, apical dendrites (10–80 µm in 
depth below the surface of brain) were chosen for analy-
sis to make sure the distance between them and amyloid 
plaques was more than 100 µm. Higher resolution images 
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(0.138 µm/pixel) were used for counting dendritic spines. 
For illustration purpose, maximal projection images were 
deconvolved (AutoQuantX3), with contrast and brightness 
adjusted.
Spine analysis
Dendritic spines were analyzed manually in ZEN 2011 
(Zeiss) by scrolling through the images in z-stacks. As the 
limitations of resolution in Z-direction, only laterally pro-
truding spines were counted, as only those could be identi-
fied with certainty. In consecutive sessions, a dendritic spine 
was determined as the same if its location did not change 
within a range of 0.5 µm along the dendrite. Otherwise, 
spines that disappeared or emerged compared to the previ-
ous imaging session were defined as formed or eliminated, 
respectively. Spine formation and elimination were nor-
malized into 100 % based on the calculations from the first 
and second imaging points. The fate of preexisting spines 
was calculated as the fraction of dendritic spines in the 
first imaging session that remained stable during the imag-
ing period. Similarly, the fate of new-gained spines was the 
fraction of formed spines in the first week of EE or match-
ing week of SC that remained stable during the rest of imag-
ing period, indicating how many gained spines incorporated 
into neural circuits. Transient spines were determined as 
spines that did not survive more than 1 week and referred to 
the stability of gained spines in a short-term period.
Immunochemistry
Following transcardial perfusion with phosphate-buffered 
saline (PBS) and 4 % paraformaldehyde (PFA), mouse 
brains were cut into 65 µm thick sections from the soma-
tosensory cortex after being fixed in 4 % PFA overnight. 
Antibodies against GFAP (Abcam 1:500), Iba1 (Wako 
1:500) and beta-amyloid (4G8, BioLegend, 1:500) were 
used to detect activated astrocytes, microglial, and amyloid 
beta, respectively. Anti-rabbit Alexa 647 antibody (Invitro-
gen 1:1000) was used as the secondary antibody. To stain 
amyloid plaques, sections were incubated with 145 µm 
methoxy-X04 in PBS for 30 min and then washed with 
PBS. After mounting on glass coverslips by fluorescence 
mounting medium (Dako), sections were imaged using 
LSM 780 confocal microscope (Zeiss). Glial activation, 
plaque load, or amyloid pathology was quantified as the 
area with positive staining relative to the cortex area after 
maximal projection of confocal stacks.
Western blot
10 % cortical tissues (w/v) were homogenized on ice in 
lysis buffer with protease inhibitors (Roche), followed by 
centrifugation at 500 rpm for 1 min. The supernatant was 
collected and protein concentrations were adjusted by the 
bicinchoninic acid assay to ensure the same amount of pro-
tein being loaded for each sample (80 µg). Samples were 
mixed with SDS-containing sample buffers and incubated at 
100 °C for 20 min. After electrophoresed on 12 % sample 
gel, proteins were transferred into polyvinylidene difluoride 
membrane (Millipore). The primary antibodies against 
IL-1β (Cell signaling), IL-1 RA (Thermo Scientific) and 
tubulin (Santa Cruz) were used at 1: 1000 concentrations for 
immunoblotting. Protein bands were quantified by ImageJ.
Quantitative real‑time PCR
For gene expression analysis in brain tissue, RNA extrac-
tion was performed using TRIzol (Invitrogen). Random 
hexamer primers, oligo dTs and Superscript II reverse tran-
scriptase (Invitrogen) was used for generation of cDNA. 
For quantitative real-time RT-PCR, the LightCycler480 
system (Roche) and the corresponding SYBR Green detec-
tion format was used. Beta-2-microglobulin (β2M) was 
used as a housekeeper. All analyses were conducted as 
triplicates. Primers for β2M were designed using Primer3 
software. Sequences for the primers were as follows: β2M 
forward, 5′-TGTCTTTCAGCAAGGACTGG-3′; β2M 
reverse, 5′-GATGCTGCTTACATGTATCG-3′; IL-1β for-
ward 5′-GGCTGGACTGTTTCTAATGC-3′; IL-1β reverse 
5′-ATGGTTTCTTGTGACCCTGA-3′ [55].
Statistics
For statistical analysis and comparison, GraphPad Prism 5 
was used. In the longitudinal measurements of spine analy-
sis, extra sum-of-squares F test was used when data were 
fitted with a line using the nonlinear regression. Comparison 
among groups was performed using one-way ANOVA fol-
lowed by Newman–Keuls post-test. Two-tailed Student t test 
was used in comparison between two different groups. The 
numbers of mice were 4–6 per group for in vivo imaging. 
8–12 dendrites were imaged in each mouse. The length of 
each dendrite was 25–35 µm and the number of spines was 
normalized to the dendritic length. Data are presented as 
mean ± SEM. N refers to the number of mice; p < 0.05 was 
defined as statistically significant (* p < 0.05, ** p < 0.01).
Results
Adaptive structural plasticity of dendritic spines is 
impaired in deltaE9 mice at the age of 4–5 months
Replicating the preclinical stages of AD [1, 44], 4–5-month-
old deltaE9 mice develop amyloid deposits without cognitive 
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decline [4, 14, 27, 34, 50]. In agreement with the normal cog-
nitive state, our previous study observed normal spine density 
and dynamics on dendrites that were far away from amyloid 
plaques in deltaE9 mice at this age [58]. To further examine if 
activity-induced structural spine plasticity on these dendrites 
is disturbed in preclinical AD, we housed deltaE9 mice at the 
age of 4–5 months under enriched environment (EE) over 
5 weeks and monitored the apical tufts of layer V pyramidal 
neurons in the somatosensory cortex (Suppl. Figure 1). EE, 
which provides a spectrum of synaptic inputs and thus leads 
to adaptive synaptic alterations within the adult brain [30, 31, 
38], induced a steady increase of spine density in the control 
group (Fig. 1a, c). In contrast, EE failed to increase spine 
density in deltaE9 mice (Fig. 1a, c). Of note, unlike control 
mice demonstrating gradual decline in dendritic spine elimi-
nation upon EE, the rate of spine elimination in deltaE9 mice 
remained unaltered (Fig. 1d). EE did not change the rate of 
spine formation in both groups (Fig. 1e). Moreover, during 
the imaging period, the density and dynamics of dendritic 
spines remained unchanged, when mice were housed under 
standard conditions (SC, Fig. 1b, c–e). Thus, EE-induced 
decrease in spine elimination and subsequent increase in 
spine density were absent in deltaE9 mice.
To find out how preexisting neural networks react to the 
stimulation of EE, we tracked the fate of dendritic spines 
that existed in the first imaging session over the whole 
period of enrichment. Interestingly, in control and deltaE9 
genotypes, less preexisting spines survived when mice 
were housed under EE (Fig. 1f, g). This indicated a break-
down of the established neural networks in both groups 
during EE. Furthermore, the fate of spines that were newly 
formed in EE or SC was also monitored. A higher number 
of gained spines remained stable during EE in control mice, 
but not in deltaE9 mice (Fig. 1h–j). Also, a direct compari-
son between control and deltaE9 mice revealed that the 
elimination rate of newly gained dendritic spines induced 
by EE was higher in the AD mouse model (Suppl. Fig. 2). 
These results suggest the failure of building up novel neural 
networks induced by EE in deltaE9 group. Collectively, our 
data imply that the reorganization of neural networks upon 
EE is impaired in preclinical stages of AD.
Reduction of BACE1 in deltaE9 mice restores the 
response with an increase in spine density upon EE
Full-length APP is processed to yield amyloid beta, the 
principal component of amyloid plaques, through sequential 
enzymatic cleavage by β- and γ-secretases. To investigate 
if elevated amyloid beta levels contribute to the impaired 
adaptive spine plasticity in deltaE9 mice, we crossed del-
taE9 mice with BACE1 knockout mice to obtain deltaE9 
genotype containing a heterozygous BACE1 gene knockout 
(deltaE9/Bace +/−). BACE1 is the primary β-secretase. Of 
note, the density and dynamics of dendritic spines in del-
taE9/Bace +/− genotype remained unchanged compared 
to control or deltaE9 mice, when they were housed under 
SC (Suppl. Fig. 3b–d). Partial reduction of BACE1 activity 
dramatically reduced amyloid plaques, glial cell activation 
and amyloid pathology (Fig. 2, Suppl. Fig. 4 and Suppl. 
Fig. 5). Unlike deltaE9 group, deltaE9/Bace +/− mice 
gained the adaptive increase in spine density housed under 
EE (Fig. 3a, b). To our surprise, the increase in spine density 
was caused by boosting spine formation (Fig. 3e) instead of 
decreasing spine elimination (Fig. 3d), which was opposite 
to the observations in the control group (Fig. 1d, e). In addi-
tion, the fates of spines that existed before or were newly 
formed after EE were indistinguishable between different 
housing conditions (Fig. 3f, g). An increased fraction of 
transient spines (Fig. 3c) suggested that the newly gained 
spines induced by EE were unstable over 1 week. In del-
taE9 or control mice, the increased transient fraction during 
EE was not observed (data not shown). Taken together, EE 
induced spine density increase but failed to remodel neural 
circuits in deltaE9/Bace +/− mice. These deficits in neural 
network remodeling appear to be caused by the reduction of 
β-secretase, as similar findings have been observed in Bace 
+/− mice (Suppl. Figure 6). The restoration of adaptive 
spine density increase suggests removal of amyloid plaques 
might ameliorate the impaired adaptive plasticity of den-
dritic spines in preclinical AD. 
Pioglitazone rescues the deficits of adaptive dendritic 
spine plasticity in deltaE9 mice
As the imaged dendrites were located in amyloid plaque-
free brain regions [58], it was plausible to hypothesize 
that diffusible factors originating from amyloid deposits 
might contribute to the lack of response of spine density 
upon EE, which was restored by the removal of plaques 
(Fig. 3b). Particularly, it is known that amyloid plaques 
are surrounded by activated glial cells that are known to 
Fig. 1  Adaptive plasticity of dendritic spines is impaired in deltaE9 
mice. a, b Two-photon micrographs of GFP-labeled apical dendrites of 
layer V pyramidal neurons. Mice were housed in standard conditions 
(SC) and imaged twice in a week apart before being housed in enriched 
environment (EE) (a). In b, mice were housed in SC throughout the 
experiment. Empty or dark arrows point to eliminated or formed spines 
compared to previous imaging session. Blue arrowheads mark spines 
that existed in the first imaging session and were stable over the entire 
imaging period while red arrowheads represent gained spines in the 
first week of EE or matching period of SC that survived over the rest 
of imaging period. c–e Quantifications of relative spine density, frac-
tion of eliminated or formed spines in mice housed under EE (above) 
or SC (below). f, g Fractions of spines from the first imaging session 
that remained stable during the whole imaging period. h, i Fractions of 
gained spines in the first week of EE or matching period of SC that 
remained stable during the whole imaging period. j The data at day 43 
from h and j were compared by one-way ANOVA. Scale bar 2 µm
▸
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release pro-inflammatory cytokines [53]. To investigate if 
these cytokines caused the impaired adaptive plasticity, we 
treated deltaE9 mice with pioglitazone, a PPAR-gamma 
agonist, which inhibits the production of pro-inflamma-
tory cytokines without affecting synaptic plasticity [6, 
25] (Suppl. Figure 7). Pioglitazone treatment successfully 
rehabilitated the steady increase of spine density in deltaE9 
mice during exposure to EE (Fig. 4a, b). Like in control 
mice, the EE-induced spine density increase resulted from 
the gradual decline in spine elimination, while the rate of 
spine formation was unchanged (Fig. 4d, e). Moreover, less 
preexisting spines and more gained spines were observed 
during EE, when deltaE9 mice were fed with pioglitazone 
(Fig. 4f, g). The fraction of transient spines also remained 
unchanged (Fig. 4c). These results indicate that the fail-
ure of remodeling neural networks upon EE in deltaE9 
mice is ascribed to the up-regulation of pro-inflammatory 
cytokines.
IL‑1 RA rehabilitates the impaired adaptive plasticity 
of dendritic spines in deltaE9 mice
The known deleterious effects of interleukin-1β (IL-1β), 
a key mediator of the inflammatory response in AD, on 
synaptic plasticity [48] prompted us to examine whether 
up-regulated levels of IL-1β undermined the adaptive spine 
plasticity. Consistent with previous reports [33, 47, 55], 
the expression of IL-1β was indeed significantly enhanced 
in deltaE9 mice (Fig. 5a). To diminish IL-1β activity, we 
injected lentivirus (LV) expressing interleukin-1 receptor 
antagonist (IL-1 RA) [49] into the somatosensory cortex 
(Fig. 5b). IL-1 RA has previously been found not to alter 
spine density, LTP, spatial memory and synaptic markers in 
wild-type mice [9]. In this study, we found that IL-1 RA 
rectified the adaptive gain of spines upon EE in deltaE9 
mice, accompanied with the gradual decline in spine elimi-
nation instead of rising spine formation (Fig. 6a, b, d, e). 
Also, the fate of spines that existed before or newly formed 
during EE was normalized in deltaE9 mice administered 
with IL-1 RA (Fig. 6f, g). In addition, the fraction of tran-
sient spines was unchanged (Fig. 6c). Taken together, these 
data suggest up-regulated IL-1β perturbs EE-induced reor-
ganization of neural networks.
Discussion
As excitatory postsynaptic compartments, dendritic spines 
receive and integrate informational input from presynaptic 
terminals [57]. This function is supposed to be disturbed 
Fig. 2  Partial reduction of 
BACE1 in deltaE9 mice greatly 
decreases amyloid plaque load 
and subsequent glial cell activa-
tion. a Immunohistochemical 
labeling of amyloid plaques 
(blue) and activated astrocytes 
(GFAP, red) or microglia (Iba-1, 
red) in the cortex. Scale bar 
300 µm. b–d Quantifications 
of area with plaque load and 
activated glial cells in deltaE9 
and deltaE9/Bace +/− mice at 
the age of 6–7 months
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at the very early stages of AD pathogenesis, which may 
explain why synaptic loss is a much better indicator for 
cognitive impairment in AD than Aβ burden or neuronal 
loss [41]. With the advent of cognitive decline, irreversible 
damage may have already occurred. Prevention strategies 
in the asymptomatic stages of AD are therefore warranted.
Fig. 3  Reduction of BACE1 
restores the spine density 
increase, but not neural circuit 
remodeling, upon EE in 
deltaE9 mice. a Two-photon 
micrographs of GFP-labeled 
apical dendrites. DeltaE9/Bace 
+/− mice were housed under 
SC (above) or EE (below). 
Empty or dark arrows point to 
eliminated or formed spines 
compared to previous imaging 
session. Blue arrowheads mark 
spines that existed in the first 
imaging session and were stable 
over the entire imaging period, 
whereas red arrowheads rep-
resent gained spines in the first 
week of EE or matching period 
of SC that survived over the rest 
of imaging period. b–e Quantifi-
cations of relative spine density, 
fraction of transient, eliminated 
or formed spines. f, g Fraction 
of spines in the first imaging 
session or gained spines in the 
first week of EE and matching 
week of SC that survived over 
the imaging period. Scale bar 
2 µm
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Preclinical AD is replicated in young deltaE9 mice 
that develop amyloid deposits before the onset of cog-
nitive decline [4, 14, 27, 34, 50]. In this study, we found 
that 4–5-month-old deltaE9 mice did not increase dendritic 
spine density when housed under EE in contrast to con-
trol mice. The novel external environment also failed to 
remodel neural networks in these transgenic mice. Reduc-
tion of BACE1 activity in deltaE9 mice reduced the 
Fig. 4  Pioglitazone recovers 
the observed impairments of 
spine structural plasticity in 
deltaE9 mice. a Two-photon 
micrographs of GFP-labeled 
apical dendrites. DeltaE9 mice 
were fed with pioglitazone dur-
ing EE or a matching period of 
SC. Empty or dark arrows point 
to eliminated or formed spines 
compared to previous imaging 
session. Blue arrowheads mark 
spines that existed in the first 
imaging session and were stable 
over the entire imaging period 
while red arrowheads represent 
gained spines in the first week 
of EE or matching period of SC 
that survived over the rest of 
imaging period. b–e Quantifica-
tions of relative spine density, 
fraction of transient, eliminated 
or formed spines. f, g Fraction 
of spines in the first imaging 
session or gained spines in the 
first week of EE and matching 
week of SC that survived over 
the imaging period. Scale bar 
2 µm
243Acta Neuropathol (2016) 131:235–246 
1 3
deposition of Aβ and restored the increase of spine density 
during EE, but not the impaired reorganization of neural 
networks. However, anti-inflammatory treatments, piogl-
itazone and IL-1 RA, successfully rescued the spine den-
sity increase and neural network remodeling upon EE in 
deltaE9 mice. These results suggest that neuroinflamma-
tion contributes to impaired adaptive plasticity of dendritic 
spines in preclinical stages of AD.
Structural plasticity of dendritic spines refers to the 
change of their distribution in response to experience 
[12]. Learning and sensory experience have been reported 
to remodel neural connections through de novo growth 
and loss of dendritic spines, which provides a structural 
substrate for adaptive behaviors. Spine density increases 
after spatial learning tasks or manipulations that inten-
sify sensory inputs [26, 28], while deprivation of sensory 
experience leads to a decrease in spine density [52]. This 
structural synaptic plasticity may substantially boost infor-
mation storage capacity in the brain [7]. The failure to 
increase spine density in young adult deltaE9 mice upon 
EE suggests an impairment of experience-dependent struc-
tural plasticity in asymptomatic stages of AD, before spine 
loss occurs. In addition, stabilized newly formed spines and 
destabilized preexisting spines in novel experience reflect 
a rewiring of neural networks, which facilitates a quicker 
adaption of brain to the same situation in the future [19, 
54, 56]. Interestingly, the ability to dismantle the preexist-
ing neural networks in novel external environment remains 
intact in deltaE9 mice. However, deltaE9 mice fall short of 
the establishment of novel neural networks. These results 
imply that experience-dependent demolition and construc-
tion of neural networks are two processes that are inde-
pendent from each other.
BACE1 initiates the proteolytic process of APP into 
Aβ, which accumulates to form amyloid plaques. As Aβ is 
believed to play a central role in AD, BACE1 becomes an 
attractive drug target. Indeed, partial reduction of BACE1 
activity leads to dramatic reductions on amyloid plaque 
burden and synaptic deficits with a small decrease of Aβ 
levels in young AD transgenic mice [29]. However, phar-
macological inhibition of BACE1 impairs structural and 
functional synaptic plasticity implying its physiological 
role in dendritic spines [11]. The boosted transient spines, 
which contribute to increased spine formation, in deltaE9/
Bace +/− mice during EE indicate the maintenance of 
experience-dependent synaptic rearrangement requires 
physiological level of BACE1 activity. It still remains 
unclear, whether BACE1 itself or its substrates are involved 
in synaptic physiology.
Amyloid deposition, driving neuroinflammation, is 
associated with activated glial cells and the release of pro-
inflammatory cytokines. These soluble mediators, IL-1β in 
particular, directly and extensively disturb synaptic trans-
mission and plasticity. IL-1β regulates the expression and 
phosphorylation of glutamate receptors on dendritic spines 
[36]. The altered sensitivity of receptors to synaptic gluta-
mate modulates synaptic plasticity. In addition, IL-1β dis-
rupts BDNF signaling cascades and thereby prevents activ-
ity-driven formation of filamentous actin in spines, which 
is required for spine structural plasticity [48]. The restora-
tive effects of pioglitazone and IL-1 RA demonstrated 
herein implicate a deleterious role of IL-1β in experience-
dependent spine structural plasticity preceding cognitive 
impairment in AD.
Of note, numerous clinical studies have demonstrated 
that anti-inflammatory treatment reduces dementia risk or 
delay the onset of AD [3, 8, 18], although anti-inflamma-
tory drugs in clinically manifested AD failed to be proven 
effective [15, 24]. These trials suggest prevention of inflam-
matory processes is beneficial at the preclinical stages of 
AD. Our data confirm that neuroinflammation caused 
impairments of spine structural plasticity is curable by 
anti-inflammatory treatment in a preclinical mouse model 
of AD. This finding implies the normalization of adaptive 
Fig. 5  Elevated expression of 
interleukin-1β in deltaE9 mice 
and exogenous interleukin-1 
receptor antagonist produced by 
lentivirus infection. a By quan-
titative real-time PCR (left) and 
western blot (right), the expres-
sion of interleukin-1β (IL-1β) 
was found to be increased in 
deltaE9 mice. b Interleukin-1 
receptor antagonist (IL-1 RA) 
was overexpressed in soma-
tosensory cortex after 1 month 
of lentivirus injection, as illus-
trated by western blot images 
and quantification
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structural plasticity of dendritic spines may correlate with 
the beneficial effects of anti-inflammatory treatment in pre-
clinical AD patients.
We conclude that our in vivo dendritic spine analysis 
reveals that neuroinflammation, caused by amyloid deposi-
tion, undermines the adaptive changes of neural networks 
Fig. 6  IL-1 RA rescues the 
impaired adaptive plasticity 
of dendritic spines in deltaE9 
mice. a Two-photon micro-
graphs of GFP-labeled apical 
dendrites of layer V pyramidal 
neurons. Mice were housed 
in SC (above) or EE (below). 
Empty or dark arrows point to 
eliminated or formed spines 
compared to previous imaging 
session. Blue arrowheads mark 
spines that existed in the first 
imaging session and were stable 
over the entire imaging period 
while red arrowheads represent 
gained spines in the first week 
of EE or matching period of SC 
that survived over the rest of 
imaging period. b–e Quantifica-
tions of relative spine density, 
fraction of transient, eliminated 
or formed spines. f, g Fraction 
of spines in the first imaging 
session or gained spines in the 
first week of EE and matching 
week of SC that survived over 
the imaging period. Scale bar,  
2 µm
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upon novel external environment before the occurrence of 
dementia, providing new insights for a possible benefit of 
anti-inflammatory treatments in preclinical AD.
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